Investor Relations :: Pieris Pharmaceuticals, Inc. (PIRS)

Latest News

Sep 8, 2022

Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

View Press Release

Aug 24, 2022

Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS

Aug 4, 2022

Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

View All News

Investor Presentation

View Presentation

H.C. Wainwright 24th Annual Global Investment Conference

View Event View All

Q2 2022

Quarter Ended Jun 30, 2022

Earnings Release

Earnings Webcast

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Report

For Fiscal Year Ending Dec 31, 2021

Company Overview

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies.

View Management Team View Board of Directors

Investor Contact Information

Company

Pieris Pharmaceuticals, Inc.
255 State Street, 9th floor
Boston, MA 02109
USA
T: + 1 (857) 246-8998
info@pieris.com

Investor Relations

Maria Kelman
Executive Director, Investor Relations
T: +1-857-327-7631
kelman@pieris.com

Transfer Agent

Computershare
P.O. Box 43006
Providence RI 02940-3078
T: 1-877-373-6374 (US, Canada, Puerto Rico) or 1-781-575-3100 (non-US)
web.queries@computershare.com
www.computershare.com/investor

Courier Delivery
150 Royall St.
Suite 101
Canton, MA 02021